ArticlePloS one2018

Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.

Alessandra Bisagni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.